Replies to post #216829 on Biotech Values

[DewDiligence]

Evolus—(EOLS)—completes IPO despite the FDA’s 483 citation at Daewoong’s Korea manufacturing plant (#msg-137992785), selling 5.75M* shares @$12.00—the bottom of the projected $12-14 range:

$EOLS Evolus prices #IPO. 5M shares at $12/share

— Bio Stocks™ (@BioStocks) February 8, 2018

Caveat emptor!!

*Assuming exercise of underwriter’s option.